Definium Reports Positive Phase 3 DT-120 Results

Definium Therapeutics says its DT-120 formulation of lysergide improved anxiety and depression symptoms in three phase 3 studies.

Updated on Nov. 19, 2026 in Mental Health

Definium Reports Positive Phase 3 DT-120 Results

Live Poll

Should psychedelic drugs like LSD be approved as treatments for anxiety or depression?

On September 14, 2026, Definium Therapeutics announced positive topline results from its Panorama phase 3 study of DT-120 in generalized anxiety disorder, following earlier topline data from the Voyage and Emerge studies. The company plans to file a new drug application with the U.S. Food and Drug Administration in the first half of 2027.

Why it matters

Generalized anxiety disorder has seen no new drug approval in just under 20 years, so a candidate showing sustained improvement after a single dose could add a new treatment option. Definium is pursuing broad labels covering both generalized anxiety disorder and major depressive disorder.

The Voyage study enrolled 214 participants and the Panorama study enrolled 245, with both generalized anxiety disorder trials showing placebo-adjusted improvements of 5.4 and 5.1 points at week 12 after one dose of DT-120 100 µg. Whether these gains persist beyond the 12-week double-blind period and the 40-week extension has not been detailed in the reported topline figures.

The players

Definium Therapeutics

Definium Therapeutics is a company developing DT-120, a pharmaceutically optimized formulation of lysergide, for psychiatric conditions including generalized anxiety disorder and major depressive disorder.

Dan Karlin

Dan Karlin is a psychiatrist and the chief medical officer involved in communicating the DT-120 clinical trial program's results.

The details

The DT-120 formulation is an orally disintegrating tablet of lysergide that reached efficacious exposure in about 30 minutes, compared with about 1 hour for the earlier powder-in-capsule version. Both generalized anxiety disorder studies included a 12-week double-blind part A and a 40-week extension, and adverse events were almost entirely confined to the day of dosing with no drug-related serious adverse events reported.

Timeline

  1. August 12, 2026: Psychiatric Times published an article on the DT120 phase 3 generalized anxiety trial results.

  2. September 14, 2026: Definium announced positive topline results from the Panorama study.

  3. First half of 2027: Definium plans to file a new drug application with the FDA.

Health Landscape

The DT-120 phase 3 program would be the first new generalized anxiety disorder treatment approved in just under 20 years if it clears FDA review. The results extend a renewed clinical interest in psychedelic-derived compounds for psychiatric conditions that existing therapies have not fully addressed.

If approved, DT-120 would give people with generalized anxiety disorder or major depressive disorder a new treatment option with a single-dose regimen in the trial design. Trial participants' adverse events were largely limited to the day of dosing, but the product's eventual cost, access and label restrictions remain unknown.

The takeaway

A single-dose candidate that shows sustained symptom improvement in trials would mark a meaningful shift for patients who have limited options for anxiety and depression. Readers should watch for the FDA filing and any later data from the Ascend study before drawing conclusions about its benefit.

What happens next

Definium Therapeutics plans to file a new drug application for DT-120 with the U.S. Food and Drug Administration in the first half of 2027.

Further reading

For more on new approaches to psychiatric care, see Mental Health.

More information

Read the full Definium press release on Panorama topline results on BusinessWire.

Source note: This article includes information reported by Psychiatrictimes.

Live Poll

Should psychedelic drugs like LSD be approved as treatments for anxiety or depression?